---
title: "Resume"

format:
  html: default
  # pdf: default
---

------------------------------------------------------------------------

# Francesco Neri

<i class="bi bi-geo-alt-fill"></i> San Francisco

**Summary**

-   Ph.D.-trained aging biologist with 6+ years of productive wet lab research experience, coupled with proficiency in R programming for data analysis and visualization.
-   Extensive experience in high-content imaging, primary human cell culture, and assay development
-   Strong communication skills and operational leadership in both academic and startup environments.

**Skills**: Primary Human Cell Culture üûÑ Molecular & Cellular Biology üûÑ Assay Development üûÑ R programming üûÑ Data Visualization & Communication üûÑ Project Management

## Experience

**2024 - 2026**

##### **Director of Research & Operations** \| NeuroAge Therapeutics \| San Francisco, CA

-   First employee. Set up NeuroAge's laboratory infrastructure, including procurement of equipment, negotiating with vendors, and securing permits to ensure compliance with health and safety regulations.
-   Led target validation efforts, generating preliminary data that supported the submission of grant applications. This included the development of plate-based assays to assess drug response using live-cell imaging.
-   Oversaw the clinical operations of the NeuroAge Test. Responsibilities included contributing to the cloud-based analysis pipeline for transcriptome and whole-genome sequencing data, the development of a custom CRM system, and coordination with partner services (MRI centers, phlebotomy services, and sequencing companies).

**2021 - 2024**

##### **Biology of Aging PhD Student** \| Campisi Lab \| Buck Institute & University of Southern California \| Novato, CA

-   Led multiple collaborative projects with other Buck and external research groups, which resulted in 2 first-author publications. These projects entailed developing a high-throughput imaging method to measure senescence burden and using high-content image analysis to identify sub-populations of senescent cells with different sensitivity to senolytic treatment.
-   Supported the organization and coordination of multiple international aging conferences, including managing all volunteer operations for the Seno-Therapeutic Summit 2023 and assisting with the Longevity Summit 2022, 2023, and 2024.

**2019 ‚Äì 2021**

##### **Research Associate** \| Campisi Lab \| Buck Institute \| Novato, CA

-   Created a step-by-step workflow to generate and analyze senescent-associated secretory phenotype (SASP) samples, leading to a first-author publication. This involved collecting several protocols developed by colleagues and carefully distilling them into a generalized and clear workflow.

-   Aided multiple projects led by other lab members, which resulted in 2 publications in peer-reviewed journals. My role involved preparing senescent samples using primary human cell strains.

-   Performed lab managing duties, including setting up centralized laboratory resources to share tested protocols and reagents among lab members, general maintenance of lab equipment, and purchasing new instruments.

**March 2019 ‚Äì September 2019**

##### **Master‚Äôs Degree Intern** \| Campisi Lab \| Buck Institute \| Novato, CA

-   Contributed to characterizing the heterogeneity of the senescent-associated secretory phenotype (SASP) from cell culture senescence models, which resulted in a published manuscript in a peer-reviewed journal. Specifically, I prepared SASP samples, which involved culturing primary human cell strains, inducing cellular senescence in such cell culture models, and validating senescence induction via multiple molecular biology assays (e.g. immunocytochemistry, RT-qPCR, western blotting).

**February 2017 ‚Äì April 2017**

##### **Bachelor‚Äôs Degree Intern** \| Perini Lab \| University of Bologna \| Bologna, Italy

-   Established MYCN potential role in the upregulation of plasma membrane transporters SLC7A1 and SLC7A2 as measured by a luciferase assay in a MYCN-inducible neuroblastoma cell line. This involved the cloning of SLC7A1 and SLC7A2 promoter regions into a luciferase reporter plasmid, their transfection into the neuroblastoma cell line, and carrying out luciferase assays.

## Publications

```{r publication_details, echo=FALSE, eval=FALSE}

library(tidyverse)
library(rcrossref)

dois <- c("10.14336/ad.2023.0812",
          "10.1101/2023.12.22.573123",
          "10.1016/j.cmet.2021.03.008",
          "10.1002/cpz1.32",
          "10.1101/2021.02.27.433188")

publication_details <- rcrossref::cr_works(dois = dois) %>%
  .$data %>% # .$author
  mutate(
    author = map_chr(author,
                 # handle NULL values
                 ~ if(is.null(.x))
                   NA
                 else {
                   # obtain string with all author names
                   .x %>%
                     mutate(
                       full_name = str_c(given, family, sep = " ")
                     ) %>%
                     pull(full_name) %>%
                     str_c(., collapse = ", ")
                }),
    date = created,
    journal = container.title %>% str_to_title() %>%
      if_else(is.na(.), "bioRxiv", .)
  ) %>%
  select(date, journal, title, author, doi, everything()) %>%
  arrange(desc(date))

publication_details

```

-   **Senescent cell heterogeneity and responses to senolytic treatment are related to cell cycle status during senescence induction**

    [Francesco Neri]{.underline}*, Shuyuan Zheng, Mark A. Watson, Pierre-Yves Desprez, Akos A. Gerencser, Judith Campisi, Denis Wirtz, Pei-Hsun Wu, Birgit Schilling

    [Aging, 2025](https://doi.org/10.18632/aging.206299)

-   **A Fully-Automated Senescence Test (FAST) for the high-throughput quantification of senescence-associated markers**

    [Francesco Neri]{.underline}, Selma N. Takajjart, Chad A. Lerner, Pierre-Yves Desprez, Birgit Schilling, Judith Campisi, Akos A. Gerencser

    [GeroScience, 2024](https://doi.org/10.1007/s11357-024-01167-3)

-   **Role of the Senescence-Associated Factor Dipeptidyl Peptidase 4 in the Pathogenesis of SARS-CoV-2 Infection**

    Stefanie Deinhardt-Emmer , Sharvari Deshpande, Koji Kitazawa, Allison B. Herman, Joanna Bons, Jacob P. Rose, Prasanna Ashok Kumar, Carlos Anerillas, [Francesco Neri]{.underline}, Serban Ciotlos, Kevin Perez, Nilay K√∂se-Vogel, Antje H√§der, Kotb Abdelmohsen, Bettina L√∂ffler, Myriam Gorospe, Pierre-Yves Desprez, Simon Melov, David Furman, Birgit Schilling, Judith Campisi

    [Aging And Disease, 2023](http://dx.doi.org/10.14336/ad.2023.0812)

-   **Oxylipin biosynthesis reinforces cellular senescence and allows detection of senolysis**

    Christopher D. Wiley, Rishi Sharma, Sonnet S. Davis, Jose Alberto Lopez-Dominguez, Kylie P. Mitchell, Samantha Wiley, Fatouma Alimirah, Dong Eun Kim, Therese Payne, Andrew Rosko, Eliezer Aimontche, Sharvari M. Deshpande, [Francesco Neri]{.underline}, Chisaka Kuehnemann, Marco Demaria, Arvind Ramanathan, Judith Campisi

    [Cell Metabolism, 2021](http://dx.doi.org/10.1016/j.cmet.2021.03.008)

-   **Comprehensive Profiling of Plasma Exosomes Using Data-Independent Acquisitions ‚Äì New Tools for Aging Cohort Studies**

    Sandip K. Patel, Roland Bruderer, Nathan Basisty, Joanna Bons, Pierre-Yves Desprez, [Francesco Neri]{.underline}, Lukas Reiter, Judith Campisi, Birgit Schilling

    [bioRxiv, 2021](http://dx.doi.org/10.1101/2021.02.27.433188)

-   **Quantitative Proteomic Analysis of the Senescence‚ÄêAssociated Secretory Phenotype by Data‚ÄêIndependent Acquisition**

    [Francesco Neri]{.underline}, Nathan Basisty, Pierre‚ÄêYves Desprez, Judith Campisi, Birgit Schilling

    [Current Protocols, 2021](http://dx.doi.org/10.1002/cpz1.32)

## Education

August 2024

**PhD in Biology of Aging** \| Buck Institute & University of Southern California \| Novato, CA

-   GPA: 4.0/4.0

October 2019

**Master's degree in Pharmaceutical Biotechnology** \| University of Bologna \| Bologna, Italy

-   Final mark: 110/110 *cum laude*

July 2017

**Bachelor's degree in Biotechnology** \| University of Bologna \| Bologna, Italy

-   Final mark: 110/110 *cum laude*
